- $2.55bn
- $1.50bn
- $139.74m
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma
Beam Therapeutics rises after gene-editing drug shows promise in rare lung and liver disease
Brief: Beam Therapeutics Announces $500 Million Strategic Financing Facility With Sixth Street
Beam Therapeutics tops Q4 profit estimates, signs financing deal
Brief: Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises
Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity
U.S. STOCKS ON THE MOVE-Applied Materials, Charles Schwab, Oracle
U.S. STOCKS ON THE MOVE-Oracle, Kratos, Masimo
U.S. STOCKS ON THE MOVE-Deere, eBay, Intuitive Machines
U.S. STOCKS ON THE MOVE-Bullish, Tapestry, Birkenstock
Beam Therapeutics up after FDA's tag for sickle cell therapy
Beam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q2 net loss widens more than expected
Brief: Beam Therapeutics Buys Early-Stage Life Sciences Company